An activating ALK gene mutation in ALK IHC-positive/FISHnegative nonsmall-cell lung cancer ALK inhibitors (i.e. crizotinib and alectinib) exhibit marked antitumor activity against nonsmall-cell lung cancer (NSCLC) with ALK rearrangements [1, 2] . The detection of ALK rearrangements is mainly carried out using fluorescence in situ hybridization (FISH). However, such analyses can yield false-positive and falsenegative results [3, 4] . Other ALK diagnostic techniques have been developed, including immunohistochemistry (IHC) for the detection of the ALK protein [5] . Several studies have shown that IHC is sensitive and specific for the determination of ALK protein expression and is an accessible, cost-effective, and rapid alternative to the ALK FISH assay. In addition, some authors have reported significant clinical improvement with crizotinib in patients with tumors that were designated as ALK-negative using FISH but were found to be ALK-positive using IHC, raising the possibility that the FISH assay may miss cases that could benefit from ALK inhibitors [4] . Recently, Ilie et al. reported that the discrepancies observed between IHC and FISH data can reflect unexpected biological events, rather than technical issues, which could potentially have a major impact on therapeutic strategies involving ALK inhibitors [3] . In our present study, we discovered an ALK kinase domain mutation (R1192G) in an ALK IHC-positive but FISH-negative NSCLC specimen ( Figure 1A) . ALK was phosphorylated when this mutation was overexpressed in the HEK293 cell line ( Figure 1B) . A focus formation assay using the NIH-3T3 cell line showed that the ALK R1192G mutation had transformational abilities, compared with the controls ( Figure 1B) . The ALK mutationoverexpressed Ba/F3 cell line showed IL-3-independent growth and was sensitive to ALK inhibitors (crizotinib and alectinib) ( Figure 1C ). The sensitivity of the cell lines to drugs was consistent with the suppression of phospho-ALK ( Figure 1C ). In vivo, the growth of tumors from the Ba/F3-ALK R1192G cell line was reduced by alectinib treatment in a dose-dependent manner ( Figure 1D ). These findings indicate that ALK inhibitors are effective against NSCLC cells carrying the ALK R1192G mutation. To the best of our knowledge, this is the first study to show that a clinical sample with ALK IHC-positive/FISH-negative findings has an ALK-activating mutation. Although this patient has not been treated with any ALK inhibitors because of no recurrence, ALK inhibitors can be effective against such NSCLC cells. Indeed, preliminary data showed that ALK IHC-positive/FISH-negative patients responded to crizotinib [4] . In clinical samples, however, no additional ALK mutation was detected in the other 49 surgically resected NSCLC specimens using next-generation sequencing (supplementary Table S1 , available at Annals of Oncology online).
In conclusion, we identified an ALK-activating mutation in an NSCLC clinical sample with ALK IHC-positive/FISH-negative findings and showed that ALK inhibitors can be effective against NSCLC cells carrying this mutation. Because clinical data are lacking, further clinical testing to validate the use of ALK inhibitors for patients with NSCLC carrying this ALK mutation should be carried out. To ensure that candidates for treatment with ALK inhibitors are not missed, further comprehensive analyses, such as NGS, should be introduced into clinical practice. 
